Pages

Tuesday, May 29, 2012

Ranbaxy Announces U.S. FDA Approval of CIP-Isotretinoin NDA

Product to be launched as Absorica™ In the U.S. Market in Q4 2012 PRINCETON, N.J., May 29, 2012 /PRNewswire/ -- Ranbaxy Laboratories Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica™, a novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne. Through a business agreement with the Canadian firm, Ciph...continued
     

No comments:

Post a Comment